Health Catalyst Address

Health Catalyst, Inc. is a healthcare data-and-analytics technology and services company headquartered in the Salt Lake City metropolitan area. It was incorporated in Delaware in September 2011 under the name HQC Holdings, Inc., and adopted its current name in March 2017, though the operating business traces to 2008 — a lineage the current CEO references directly, describing "eighteen years working with health systems" on the Q2 2026 earnings call (Q2 2026 earnings release, 6 Aug 2026). The company completed its initial public offering in July 2019.

Positioning statement (150 words). Health Catalyst occupies the healthcare-specific layer of the provider data stack: it ingests, normalises and governs clinical, claims, financial and operational data for health systems, then sells analytics applications and human expertise on top of it. Its distinctive asset is not infrastructure — management now openly concedes the data-platform layer has commoditised against Databricks, Snowflake and Microsoft — but a proprietary corpus of measured improvement outcomes accumulated over 18 years and more than 2,000 documented, client-verified improvements. The 2026 strategy under new CEO Ben Albert reframes the company as a "healthcare intelligence" business: an AI-enabled improvement layer that quantifies, prioritises and sequences cost, clinical-quality, ambulatory-growth and consumer interventions. Execution risk is acute. The company is simultaneously migrating clients off its legacy DOS platform, restructuring its cost base, having divested its most profitable software unit, and carrying an accumulated deficit above USD 1.5 billion against a market capitalisation near USD 135 million.

2.1 The company's own description

The FY2025 Form 10-K opens with an unchanged framing: "We are a leading provider of data and analytics technology and services to healthcare organizations. Our Solution comprises our cloud-based data and analytics platform, software applications, and expertise. Our clients, which are primarily healthcare providers, use our Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements. We envision a future where all healthcare decisions are data-informed."

The company organises its self-description around three components: (i) the Ignite Data & Analytics Platform, a healthcare-specific, cloud-based, open and self-service ecosystem for analytics, application development and interoperability; (ii) Applications, software analytics products built on Ignite across five focus areas — Clinical Improvement, Revenue & Cost Improvement, Ambulatory Operations, Measures & Registries, and Data & Analytics; and (iii) Expertise, a services organisation of data engineers, data scientists, clinicians and healthcare administrators delivering implementation, analytics, abstraction, cost-accounting and Tech-Enabled Managed Services (TEMS).

The company describes its operating philosophy through the "Health Catalyst Flywheel": team-member engagement drives quality of work, which drives measurable client improvement, which drives client trust, renewal, expansion and referral, which drives predictable financial performance. This construct is not decorative — it is referenced in the executive compensation design disclosed in the 10-K/A, where annual bonus outcomes for all team members are tied to client outcomes, growth and Adjusted EBITDA.

By August 2026 the company's boilerplate had been rewritten materially. The Q2 2026 release describes Health Catalyst as "a healthcare intelligence company designed to accelerate measurable improvement for health systems across cost, clinical, and consumer performance," backed by "deep domain expertise, proprietary AI-driven technology, and $2.8 billion in documented outcomes." The shift from "data and analytics technology and services" to "healthcare intelligence" is the clearest single marker of the strategy reset.

2.2 Independent characterisation

Health Catalyst is, in economic terms, a hybrid of three businesses that have historically been bundled and are now being deliberately unbundled.

The first is a healthcare data-platform business (formerly DOS, now Ignite) sold on multi-year subscription. This is the anchor relationship: it creates switching costs, it is the surface on which applications are sold, and it is the layer under most competitive pressure. Management's Q1 2026 admission that "healthcare data infrastructure has increasingly commoditized" is a significant concession from a company whose original thesis was that healthcare data warehousing required purpose-built architecture.

The second is a portfolio of point-solution applications, largely assembled through twelve acquisitions since 2018 — patient engagement (Twistle, Upfront), care orchestration (Lumeon), oncology (Carevive), registries (ARMUS, CRStar/ERS), measures (MeasureAble/Able Health), cost accounting (PowerCosting), labour management (PowerLabor), interoperability (Ninja Universe/KPI Ninja), cybersecurity (Intraprise), and — until 31 July 2026 — mid-revenue-cycle (Vitalware). These applications carry higher gross margins than services and are the intended vehicle for AI monetisation.

The third is a professional services and managed-services organisation. This is the structurally problematic segment: FY2025 adjusted gross margin of 18.3% and GAAP gross margin of 12.8%, on revenue that declined 8% year over year. Management now guides this business to roughly USD 55 million annually exiting 2026, versus USD 111.7 million in FY2024 — a deliberate contraction of nearly half.

Revenue model mix. The company reports two revenue lines only:

Technology revenue is predominantly recurring subscription; professional services is a mix of recurring managed services (TEMS) and project-based, non-recurring engagement revenue. The company explicitly flags fluctuation in "project-based, non-recurring revenue" as a principal risk in every earnings release reviewed.

Value-chain position. Health Catalyst sits between the EHR system of record (Epic, Oracle Health) and the health system's executive decision-making layer. It does not own the transactional workflow; it owns the analytic abstraction of it. This is simultaneously its defensibility (EHR vendors historically underinvested in cross-source analytics) and its vulnerability (EHR vendors are now investing heavily, and the 10-K names "the increasing market share of EHR companies in data analytic services, patient engagement and other parts of our Solution" as a specific cause of contract termination risk).

Customer types and end-markets. Academic medical centres, integrated delivery networks, community hospitals, large physician practices, Accountable Care Organizations, health information exchanges, health insurers, life-science organisations, healthcare technology vendors (for cybersecurity) and other risk-bearing entities. Named clients in the FY2025 10-K: Allina Health, AlohaCare, Baylor Scott & White Health, Carle Health, Children's Hospital of Orange County, Community Health Network, Contexture, INTEGRIS Health, Lifepoint Health, Mass General Brigham, MultiCare, Queen's Health System, Temple University Health System, UnityPoint Health, UPMC. No client represented more than 10% of total revenue in FY2025, FY2024 or FY2023 (10-K FY2025).

10.1 Stated strategy — verbatim themes from the FY2025 Form 10-K

The 10-K sets out five growth strategies:

1. "Grow our overall client base." The company estimates its total core addressable market at more than 1,200 healthcare organizations, including health systems and risk-bearing entities, plus life-science organisations, payers, and — for cybersecurity — healthcare technology companies.
2. "Expand within our current client base." Land-and-expand from a single measurable improvement to broader engagement, including through TEMS.
3. "Add new applications and offerings." Continued investment at the analytics-applications layer, leveraging the open Ignite platform.
4. "Grow our addressable market through additional healthcare business segment adjacencies." International markets, life sciences, health insurers, health information exchanges.
5. "Selectively pursue partnerships and maximize return on acquisitions." Critically, the FY2025 10-K states: "While we do not expect to acquire new entities in the near term... In the near-term our focus is on maximizing the return on our past acquisitions." This is a formal end to the acquisition programme that defined 2018–2025.

10.2 The 2026 strategy reset (CEO Ben Albert)

The strategic logic articulated across the Q1 and Q2 2026 calls represents a genuine repositioning rather than a restatement:

• Diagnosis of the core problem. Management identified "the direct connection between our previous migration strategy and the revenue pressure we are managing this year." Setting a rigid DOS-to-Ignite timeline over two years "created a churn dynamic that is heavily impacting 2026." The prior approach forced "clients into an accelerated decision point on the migration before we had the right retention program and client-facing structure in place."
• Remediation. Abandonment of the one-size-fits-all migration in favour of a line-by-line review of every remaining client with tailored plans, including extended DOS availability.
• The commoditisation thesis. "Healthcare data infrastructure has increasingly commoditized. Durable advantage lives in the intelligence built on top of it." Named commoditising forces: Databricks and Snowflake.
• The moat claim. "Our advantage rests on something no one else has: our wealth of improvement data — the link between an intervention, its cost, and its measured outcome. Eighteen years and thousands of improvement engagements later, our proprietary dataset compounds... A new entrant cannot manufacture this dataset retrospectively."
• The AI product thesis. A growing suite of AgenTeq AI models across cost management, clinical quality, consumer experience and ambulatory growth, embedded in domain-specific applications, combining machine-learning layers and LLMs to surface opportunities, quantify impact and guide execution — "recalculat[ing] daily as conditions change."
• Structural simplification. "One company, one commercial approach, one client-facing team, and one set of standards."
• Investor posture. "We recognize that our performance has not been where we want it, and that we will be judged by the performance that we create." And in Q2: "We are prioritizing the foundation for what we believe is durable long-term transformation rather than chasing short-term results."

10.3 Announced strategic initiatives, last 24 months

10.4 Medium-term financial targets and guidance

Additional FY2026 targets: full-year adjusted gross margin below 50%; adjusted technology gross margin finishing in the low 60s; adjusted professional services gross margin in the low-to-mid teens; new bookings USD 22–26 million; stock-based compensation in mid-single digits as a percentage of revenue. Management expects to be "generally through the strains of the migration by 2027" and migration-related churn headwinds resolved "by the end of 2027." No formal multi-year revenue, margin or EBITDA target has been published under the current CEO — a material gap in the investment case that management has not yet filled.

ESG commitments: the company maintains an ESG section on its investor relations site. Quantified emissions targets are not publicly disclosed in the sources reviewed. See §20.

The FY2025 10-K organises the applications portfolio into five focus areas beneath the Ignite platform. Pricing is disclosed at the model level only: the company states it "serve[s] the majority of our clients through a subscription-based contract model." No product-level list pricing is publicly disclosed for any offering.

5.1 Platform layer — Health Catalyst Ignite (Technology segment)

Health Catalyst Ignite Data & Analytics. A healthcare-specific, cloud-based, open, flexible, scalable and self-service ecosystem for analytics, application development and interoperability, providing a single environment to integrate and organise data from disparate source systems. Ignite adapts industry-agnostic technologies (the company runs on Microsoft Azure and integrates Databricks and Azure Data Factory job scheduling) to healthcare-specific requirements. Target customer: enterprise health systems, IDNs, academic medical centres. Latest-generation platform succeeding the legacy DOS (Data Operating System). Disclosed capability set:

• Healthcare source templates — library of source starter sets for EMR, claims, financial and operational data.
• Integrated job scheduling and monitoring — unified orchestration of Databricks, Azure Data Factory and API source jobs.
• Data profiling — trend and quality analysis, platform and application health monitoring.
• Identity management — master patient and provider index, with ingestion of externally mastered data.
• Data security — sensitive-data discovery, access control and activity monitoring.
• Foundational Expert Data Collections (EDCs) — modular clinical, claims and financial data products with out-of-the-box EMR source support, usable standalone or as interoperable models.
• Terminology — complete code sets for SNOMED, LOINC, ICD, CPT and others, plus smart mappings normalised to client data.
• Data quality rules — upstream issue flagging.
• Pop Analyzer — end-user cohort building and analytics on source and normalised data.
• Data entry — client file loading into Ignite.
• Visualization tools — bring-your-own BI and AI modelling tools.
• 24x7 technical support, data-management support, and named account/program management.

Legacy DOS (Data Operating System). The predecessor platform. Management confirmed on the Q1 2026 call that it is "extending the availability of DOS" and abandoning the prior fixed migration timetable in favour of client-by-client transition plans, including options for clients to remain on DOS for an extended period.

5.2 Clinical Improvement applications

5.3 Revenue & Cost Improvement applications

Analyst note: the divestiture removed the three Vitalware products — the company's most consistently KLAS-recognised software line, with Chargemaster Management ranked Best in KLAS in multiple years — leaving PowerCosting and PowerLabor as the entirety of the Revenue & Cost Improvement portfolio. This is the most consequential portfolio change in the company's history and materially narrows the "cost intelligence" claim underpinning the AI strategy.

5.4 Ambulatory Operations applications

5.5 Measures & Registries applications

5.6 Data & Analytics applications

5.7 Services and improvement expertise (Professional Services segment)

Infrastructure, data and analytics expertise: data engineering services; analytics engineering services; implementation services; data science services; analytics strategy services (agile development workshops, data architecture and ETL support, documentation and training, measure reporting efficiency, staff augmentation); data governance services.

Tech-Enabled Managed Services (TEMS): outsourcing of specific functions such as data abstraction or analytics to Health Catalyst, frequently including re-badging existing health-system team members as Health Catalyst team members. This model is the source of both the segment's scale and its margin problem, and management identified in Q2 2026 that some clients are now bringing managed-services work back in-house.

Healthcare domain expertise: quality and process improvement strategy (organisational readiness assessments, opportunity analysis, clinical pathways, Lean methodology, clinical variation reduction); patient safety services; cost accounting services; population health and value-based care transformation services; abstraction data submission services; Health Catalyst University educational services.

Named flagship offerings. Ignite (platform), Healthcare.AI / Ignite Intelligence (AI layer), MeasureAble (regulatory), Ninja Universe (interoperability), PowerCosting (cost), Upfront and Twistle (engagement), Lumeon (orchestration), Intraprise (cybersecurity), CRStar and ARMUS Suite (registries).

All figures USD millions unless stated. Sources: Exhibit 99.1 earnings releases for FY2021/2022 (filed 28 Feb 2023), FY2023 (22 Feb 2024), FY2025 with FY2024 comparatives (12 Mar 2026), and Form 10-K FY2025.

6.1 Income statement

6.2 Margins

Note: FY2021–FY2023 GAAP gross profit was presented by the company on a "gross profit, excluding depreciation and amortization" basis; the presentation changed in FY2024 to include amortisation of acquired technology and depreciation of capitalised software in cost of revenue. GAAP gross margins for FY2021–FY2023 are therefore not comparable to FY2024–FY2025 and are flagged accordingly rather than estimated.

Revenue CAGR FY2021–FY2025: 6.5%. Technology-only CAGR: 9.0%. Professional services CAGR: 2.2%.

6.3 Balance sheet

6.4 Cash flow

6.5 Ratios

ROE and ROA computed on average balances; FY2021 excluded because FY2020 balance-sheet data was not retrieved for this dossier. ROIC and interest coverage are not meaningful in any year because GAAP EBIT was negative throughout. Cash conversion cycle is not calculable — the company carries no inventory and does not disclose the payables detail required for a meaningful DPO.

Supplementary receivables metric: days sales outstanding, computed as year-end accounts receivable divided by revenue times 365, was 74 days (FY2021), 63 (FY2022), 74 (FY2023), 68 (FY2024) and 69 (FY2025) — stable and unremarkable.

6.6 Commentary on trends, inflections and drivers

Revenue. Growth decelerated monotonically across the period: 14.2% (FY2022), 7.1% (FY2023), 3.6% (FY2024), 1.5% (FY2025). Critically, a substantial share of even that muted growth was acquired rather than organic — FY2025 revenue growth of USD 4.6 million was achieved in a year in which the company deployed USD 41.1 million on the Upfront acquisition, implying organic revenue was flat to declining. The Q2 2026 print made the underlying trajectory explicit: revenue of USD 70.5 million against USD 80.7 million in Q2 2025, a 13% decline.

Gross margin. Adjusted gross margin fell from 53.0% (FY2021–FY2022) to a trough of 48.8% (FY2024), then recovered to 51.1% (FY2025) and 51% in H1 2026. The trough was driven entirely by professional services, where adjusted gross margin collapsed from 27% to 15% between FY2021 and FY2023 as the TEMS re-badging model scaled at low incremental margin. The FY2025 recovery came from mix shift toward technology (66.9% of revenue) plus the exit of unprofitable pilot ambulatory TEMS arrangements. Technology adjusted gross margin has drifted from 69% to 63% (Q2 2026) — a genuine deterioration, attributed by management to duplicate hosting costs during Ignite migration and heavy data-loading costs for HIE client deployments.

Operating expense discipline. This is the clearest positive inflection. Sales and marketing fell from USD 87.5 million (FY2022) to USD 52.5 million (FY2025), a 40% reduction. R&D fell from USD 75.7 million to USD 49.8 million over the same period, a 34% reduction. G&A fell from USD 76.6 million (FY2023) to USD 49.6 million (FY2025). Adjusted operating expenses as a percentage of revenue improved from 40% (FY2024) to 38% (FY2025) to 37% (Q2 2026).

Stock-based compensation is the single most important normalising adjustment. SBC of USD 72.1 million in FY2022 represented 26.1% of revenue — an extraordinary figure that made Adjusted EBITDA a poor proxy for cash economics. Its reduction to USD 27.0 million (8.7% of revenue) in FY2025, with management guiding to mid-single-digit percentage of revenue for FY2026, materially improves the quality of the Adjusted EBITDA line. This is arguably the most underappreciated improvement in the five-year record.

Adjusted EBITDA trajectory is genuinely impressive in isolation: -USD 11.2 million (FY2021) to +USD 41.4 million (FY2025), a swing of USD 52.6 million on USD 69.2 million of revenue growth. Incremental Adjusted EBITDA margin of roughly 76% demonstrates real operating leverage. The counterpoint is that this was achieved while GAAP losses widened.

The impairment inflection. FY2025 carried USD 110.2 million of goodwill and intangible impairment (USD 28.8 million at 30 June 2025, USD 81.5 million at 31 December 2025). H1 2026 added a further USD 122.5 million (USD 95.5 million in Q1, USD 27.0 million in Q2, the latter triggered by the 4 June 2026 Vitalware agreement). Goodwill has therefore collapsed from USD 259.8 million (FY2024) to USD 11.1 million at 30 June 2026 — a near-total write-off of the value assigned to a decade of acquisitions. Cumulative impairment of approximately USD 232.8 million across six quarters is a definitive accounting verdict on the acquisition programme.

Cash flow is the weakest element. Operating cash flow was negative in FY2021–FY2023, briefly positive at USD 14.6 million in FY2024, and essentially nil at USD 0.7 million in FY2025 despite USD 41.4 million of Adjusted EBITDA. The reconciliation is instructive: USD 11.5 million of working-capital outflow through payables and accrued liabilities, and roughly USD 19 million of cash interest. Free cash flow was negative in all five years. Capitalised internal-use software rose steadily from USD 6.6 million to USD 19.8 million, meaning an increasing share of development spend bypasses the income statement — a legitimate but margin-flattering practice worth monitoring. H1 2026 operating cash flow of USD 18.8 million is the first genuinely strong result, though management explicitly cautioned that Q1's cash generation was atypical and driven by billing seasonality.

Capital structure. The USD 230 million 2.50% convertible notes issued in 2020 matured in 2025 and were repaid, funded by the USD 152 million term loan drawn in 2024 plus balance-sheet cash. This transaction consumed the company's liquidity cushion: cash plus short-term investments fell from USD 392.0 million (FY2024) to USD 95.7 million (FY2025). The term loan carried approximately USD 19 million of annual GAAP interest expense — roughly 6% of revenue — and restrictive covenants that management cited as a constraint on investment. Its retirement on 31 July 2026 using Vitalware proceeds leaves the company debt-free with approximately USD 82 million of pro forma cash and short-term investments.

Dilution. Shares outstanding rose from 52.6 million to 72.0 million between FY2021 and FY2025, a 37% increase, driven by SBC vesting and acquisition stock consideration (5.7 million shares for Upfront; approximately 2 million for Intraprise). Buybacks totalled USD 15.2 million across the entire period — immaterial against the dilution.

22.1 Management guidance

Supporting FY2026 guidance elements: full-year adjusted gross margin below 50%; adjusted technology gross margin finishing in the low 60s; adjusted professional services gross margin in the low-to-mid teens; new bookings of USD 22–26 million (inclusive of Vitalware bookings through the transaction date); stock-based compensation down significantly in absolute dollars and in mid-single digits as a percentage of revenue; professional services exiting the year at approximately USD 55 million annualised; migration-related churn headwinds "generally through" by end-2027.

Implied Q4 2026: revenue of approximately USD 55–58 million and Adjusted EBITDA of approximately USD 8.6–9.1 million, computed as full-year guidance less H1 actuals (USD 141.2 million revenue, USD 19.0 million Adjusted EBITDA) less Q3 guidance. The Q3 Adjusted EBITDA trough of essentially breakeven reflects the immediate loss of Vitalware's high-margin contribution before the full quarterly run-rate of Project Nexus savings lands.

22.2 Consensus growth expectations

Formal consensus revenue and EBITDA estimates for FY2027 were not retrieved for this dossier. What can be inferred: the FY2026 exit run-rate implies an annualised revenue base of approximately USD 220–232 million entering 2027, before any FY2027 churn. Management has quantified USD 10 million of residual migration-related revenue impact in 2027. Against that, professional services stabilising at USD 55 million and technology returning to growth would be required for FY2027 revenue to hold flat. No management multi-year target has been published. Sell-side price targets cluster tightly at USD 1.75–2.00 with Hold ratings.

22.3 Bull case

1. The enterprise value is approximately USD 55 million for a business generating USD 18 million of Adjusted EBITDA and approximately USD 250 million of revenue. At roughly 3.0x EV/Adjusted EBITDA and 0.22x EV/Sales, the market is pricing terminal decline. If revenue merely stabilises at USD 230 million with a 15% Adjusted EBITDA margin and positive free cash flow, the equity is worth multiples of the current price. The company received USD 147 million for Vitalware — more than its entire market capitalisation at announcement — which establishes that discrete assets carry realisable value well above the public mark.
2. The cost transformation is real and quantified. Adjusted operating expenses fell from 40% to 37% of revenue; SBC fell from 26.1% to 8.7% of revenue and is guided lower; Project Nexus is "on track to exceed" its USD 30 million savings target; roughly USD 16.5 million of annual cash interest has been eliminated. These are cash savings against a cash-strapped P&L, and they are largely already executed rather than promised.
3. The balance sheet risk has been retired. Zero debt, no maturities, approximately USD 82 million of pro forma liquidity, and H1 2026 operating cash flow of USD 18.8 million. Goodwill has been written down to USD 11.1 million, eliminating further impairment overhang. The company can now fund a multi-year transition without financing risk — a materially different situation from twelve months ago.

22.4 Bear case

1. Revenue is in outright decline and the trough is not yet visible. Q2 2026 revenue fell 13% year over year. Q3 is guided to USD 55–56 million, a further 27% sequential decline. Dollar-based retention has fallen to 93%. USD 30 million of at-risk ARR remains, and management stated in Q2 that despite client-by-client retention work "we continue to see significant pressure in this area" and that churn "has pulled forward." Cost savings cannot outrun a shrinking top line indefinitely.
2. Adjusted EBITDA has not translated into cash in any year. Free cash flow was negative in all five fiscal years, including FY2025 with USD 41.4 million of Adjusted EBITDA. Capitalised internal-use software rose to USD 19.8 million — 28% of total technology investment — meaning reported EBITDA increasingly flatters cash economics. The FY2026 guide of USD 18–18.5 million Adjusted EBITDA against approximately USD 20 million of annual capitalised software and capex implies free cash flow near zero at best.
3. The moat thesis is unproven and the divestiture undercut it. Management asserts that durable advantage lives in the improvement-data intelligence layer, not the platform. But AgenTeq is in development, Ignite Intelligence is in "very early innings," no AI revenue is separately disclosed, and R&D expense has been cut 34% from peak. Meanwhile, the company sold Vitalware — its Best-in-KLAS cost-and-revenue asset — narrowing the "cost intelligence" proposition at precisely the moment cost intelligence became the lead use case. The strategy requires the market to fund a multi-year rebuild from a company with USD 50 million of annual R&D expense competing against Epic, Optum and the hyperscalers.

22.5 Catalysts and monitorables — next 12 months

22.6 Concluding analyst verdict (300 words)

Health Catalyst is a genuine turnaround situation with a genuinely uncertain outcome, and the market has priced it accordingly at an enterprise value of roughly USD 55 million — less than one-quarter of forward revenue.

The bear case is straightforward and currently winning. Revenue is contracting at a double-digit rate, retention has broken below 100%, the migration that was supposed to be a platform upgrade has instead become a churn event of management's own creation, and free cash flow has been negative in every year of the company's public life despite an Adjusted EBITDA line that improved by USD 52 million. The near-total write-off of goodwill — from USD 260 million to USD 11 million in eighteen months — is an unusually blunt accounting judgment on a decade of capital allocation. Guidance moved twice in five months and in the wrong direction.

The bull case is equally straightforward but requires patience the market has not extended. The company has done the hard, unglamorous work: four restructurings, stock compensation cut by two-thirds, operating expenses down nearly 40% from peak, and — decisively — the sale of Vitalware for more than the entire equity value, using the proceeds to retire all debt and roughly USD 16.5 million of annual cash interest. What remains is a debt-free business with USD 82 million of liquidity, approximately 13% penetration of its stated core market, real regulatory moats in registries and measures, and eighteen years of outcomes data that a new entrant cannot replicate.

The gating question is not whether Health Catalyst can cut costs — it has proven that — but whether technology revenue can return to growth once the migration churn clears in 2027, and whether the intelligence layer becomes a product rather than a narrative. Until bookings inflect, the shares are an option on execution, not an investment in a franchise. Position sizing should reflect that distinction.

End of dossier. All figures stated in USD. Fiscal years end 31 December. Data points marked "not publicly disclosed" or "not verified" were sought and not located in the primary sources reviewed; they have not been estimated. Where sources conflict — notably on Dollar-based Retention Rate (93% per filing versus 90% per transcript), on 52-week price range across data vendors, and on the count of client organisations (1,100 versus 1,200) — both figures are recorded with the discrepancy noted.

--